Bulk of earnings pressure in the first half of 2023, says Citi's Scott Chronert
Teva stock drops 10% as generics turnaround looks uncertain - MarketWatch
Teva Pharmaceuticals (@TevaUSA) / Twitter
Teva's generic EpiPen approved in the U.S., with perfect timing - MarketWatch
Teva Stock Sees Another Big Buy From Chairman Sol Barer | Barron's
Teva: Avoid (NYSE:TEVA) | Seeking Alpha
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Declining sales of blockbuster drug drag Teva revenue lower - MarketWatch
Teva to acquire Mexico's Rimsa for $2.3 billion - MarketWatch
Opinion: Multinationals learn the limits of being big - MarketWatch
Teva to lay off 14,000 workers in bid for survival — but some are skeptical - MarketWatch
Is the new Teva x Ugg collection fashion-forward or just plain ugly? - MarketWatch
I-Mab's IL-6 Drug Hits Primary Endpoint Goal In Mid-Stage Ulcerative Colitis Study
Teva Pharmaceuticals (@TevaUSA) / Twitter
FDA approves first rival generic EpiPen, sending Teva shares up 6% - MarketWatch
Teva Pharmaceutical CEO Talks Opioids, Lawsuits, and the Long Road Ahead | Barron's
Teva Stock Pressured From Antitrust Lawsuit Against Drug Makers | Barron's
Teva Stock Has Crumbled, and Chairman Sol Barer Is Buying Up Shares | Barron's
MarketWatch on Twitter: "Teva Pharmaceutical named Kare Schultz as its new chief executive https://t.co/pyLR2vL5Ep https://t.co/pD8godrT5C" / Twitter
What To Do After TEVA Stock Falls Below $10 Again (NYSE:TEVA) | Seeking Alpha
Generic-drug stocks slammed by report of expanded price-fixing probe - MarketWatch
Teva Pharmaceuticals - Wikipedia
